Bavarian Nordic A/S, of Copenhagen, said results from a National Cancer Institute-sponsored phase I study investigating its cancer vaccine, MVA-BN Brachyury, demonstrated for the first time that an MVA-BN-based vaccine targeting brachyury — a tumor-associated antigen overexpressed in every major solid tumor setting — can induce brachyury-specific T-cell immune responses in advanced cancer patients.